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Anti-
^
citrullinated protein/peptide antibodies (ACPA) have recently emerged as sensitive and speciﬁc
serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF)
test in the laboratory diagnostics of RA. Citrullination is a post-
^
translational modiﬁcation of arginine by
deimination, physiologically occurring during apoptosis, inﬂammation or keratinization. The presence of
several citrullinated proteins has been demonstrated in the RA synovium. The identiﬁcation of citrullinated
epitopes as targets led to the development of the ﬁrst and later second-
^
generation anti-
^
cyclic citrullinated
peptide (anti-
^
CCP) antibody assays. The anti-
^
Sa antibody has been identiﬁed a decade ago; however, recent
studies conﬁrmed that anti-
^
Sa is directed against citrullinated vimentin. The determination of ACPA may
have important prognostic signiﬁcance, since ACPA production can precede the onset of clinical RA
symptoms by years. ACPA+ individuals with early, undifferentiated arthritis may have higher risk to develop
RA. ACPA has important prognostic role during the progression of RA and it has also been associated with
pronounced radiographic progression. ACPA production has been associated with several genetic
predisposing factors, including HLA-
^
DRB1 and PTPN22 1858T alleles, as well as with environmental and
lifestyle-
^
related factors, primarily smoking and possibly, the use of oral contraceptives and excessive caffeine
intake. Thus, the assessment of ACPA, in addition to clinical, radiographic and genetic outcome measures may
be important to assess disease prognosis and aids to design effective, early therapeutic strategies.41© 2009 Elsevier B.V. All rights reserved.42
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Rheumatoid arthritis (RA) is an autoimmune-
^
inﬂammatory dis-
ease that may lead to joint destruction and disability [1]. Genetic
factors including class II major histocompatibility complex (MHC) andptide autoantibodies in association with genetic and environmental
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non-
^
MHC alleles, environmental factors and autoimmune processes
are highly involved in the pathogenesis of RA [2]. Early diagnosis and
immediate, effective therapy are crucial in order to prevent joint
deterioration, functional disability and unfavorable disease outcome
[1,3]. Currently, optimal management of RA is needed within 3–
^
6 months after the onset of disease, therefore a very narrow “window
of opportunity” is present to achieve remission [3]. Thus, reliable
outcome measures are needed in order to establish prognosis early
and to conduct good clinical practice.
Signiﬁcant amount of data have become available suggesting that
genetic factors and autoimmune-
^
inﬂammatory markers are good
indicators of outcome [2,4]. In this review, we aim to summarize
recent data regarding the predictive and prognostic value of genetic
and laboratory markers in RA.
2. Anti-
^
citrullinated protein/peptide antibodies
2.1. Synovial citrullination and production of ACPA
Citrulline is the post-
^
translationally modiﬁed, deiminated derivative
of arginine [4,5]. The arginine-
^
to-
^
citrulline transition is catalyzed by the
peptidylarginine-
^
deiminase (PAD) enzyme that has ﬁve isoforms in
mammals, PAD1-
^
4 and PAD6 [5,6]. Tissue citrullination is a physiological
process underlying epithelial keratinization, inﬂammation and
increased apoptosis [4–7]. Inﬂammatory leukocytes including RA
synovial Tand B cells,macrophages, neutrophils and synovialﬁbroblasts
express both the PAD2 and PAD4 isoforms [4,6,8]. There is relatively
small amount of citrullinated proteins in the normal synovial tissue,
whereas active citrullination has been associated with synovitis [6–8].
Citrullinated protein epitopes have been identiﬁed in extravascular
ﬁbrin deposits and extracellular ﬁbrinogen aggregates within the RA
synovium [6,7]. Filaggrin, the ﬁrst citrullinated protein identiﬁed, as
potential autoantigen in RA is an epidermal protein usually absent from
the synovium [9]. Thus, other citrullinated proteins, such as ﬁbrin or
vimentin that are abundantly expressed and citrullinated in synovial
tissues may drive autoantibody responses [8–12]. Indeed, citrullinated
ﬁbrin (CF) has been detected in RA synovial ﬂuid [12], whereas
citrullinated vimentin is expressed by synovial macrophages [10,13].
These autoantigens induce the production of anti-
^
citrullinated protein/
peptide autoantibodies (ACPA) that have been associated with
autoimmunity underlying RA [4,8,13,14]. In vivo, deiminated α and β
chains of ﬁbrin may be the dominant autoantigen in RA, while other
citrullinated proteins may cross-
^
react with CF during antibody produc-
tion [15]. Although, most studies suggest high diagnostic speciﬁcity and
sensitivity of ACPAs in RA [4,8,10,16], tissue citrullination and ACPA
production have been detected in patients with other types of arthritis,
yet less frequently [16,17]. In comparative studies, 74–
^
97%of RA, butonly
6–
^
7% of psoriatic arthritis (PsA) patients were anti-
^
cyclic citrullinated
peptide (anti-
^
CCP) positive [16,17].
2.2. Predictive value of ACPA
Patients presenting with undifferentiated polyarthritis (UDP) may
eventually develop deﬁnitive RA, remain UDP for years, ormay undergo
spontaneous remission [3]. Identifying biomarkers, suggesting the
transition of UDP to RA are of utmost importance [3,18]. ACPA may be
detected in the sera of patients years before the onset of clinical
symptoms [4,19]. In the preclinical phase, 25% of patients, who develop
RA later than 18 months, while 52% of those that develop RA within
18 months are anti-
^
CCP positive [19]. The positive ACPA serology
may predict the development of RA in patients with UDP [3,19].
2.3. ACPA as prognostic marker
Regarding its prognostic value in established RA, ACPA seroposi-
tivity has been associated with a more severe, destructive diseasePlease cite this article as: Szodoray P, et al, Anti-
^
citrullinated protein/pe
factors as indicators of disease outcome in rheumatoid arthritis, AutoimTE
D
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1course [4,8,19,20]. ACPA+ RA patients developed more erosions after
16–
^
10 years of follow-
^
up [3,18]. Seropositivity has also been associated
1with sustained inﬂammatory activity indicated by long-
^
term elevation
1of erythrocyte sedimentation rate (ESR) and disease activity score
1(DAS)28 [18,20]. Among various ACPAs, these associations could be
1conﬁrmed regarding anti-
^
CCP, anti-
^
mutated citrullinated vimentin
1(MCV), as well as anti-
^
CF [4,10,15,16,19,20].
1In an early study, the prognostic value of anti-
^
perinuclear factor
1(APF) determined by indirect immunoﬂuorescence was assessed in
1patients with early RA (duration b1 year). APF had additional value
1in differentiating RF+ and RF−
^
patients with respect to radiographic
1damage [21]. In an inception cohort of 273 patients with RA (disease
1duration b1 year), anti-
^
CCP+ patients developed more severe joint
1destruction after 6 years of follow-
^
up. While radiographic damage
1was predicted by both ACPA and IgM RF at baseline, functional
1deterioration was predicted only by RF at entry [22]. In early RA, ACF
1antibodies also had good prognostic value for radiographic
1progression after 2 years [8,15]. When serial determination of
1anti-
^
CCP was performed in 99 early RA patients at baseline and
1subsequently, within the ﬁrst 3 years, anti-
^
CCP positivity was
1associated with 5-
^
year progression of the total Sharp score (OR 3.2),
1erosion score (OR 5.3) and joint space narrowing score (OR 2.8). In
1addition, anti-
^
CCP−
^
patients had less radiographic progression than
1those with increasing anti-
^
CCP production [23]. The prognostic
1value of ACPA has also been conﬁrmed in very early RA (duration
1b3 months) [24].
1When four outcome measures were compared with respect to
1prognostic value for joint destruction after 10 years, anti-
^
CCP was the
1best indicator (OR 4.0), while the other three indicators (female sex,
1ESR and RF) showed less potential (OR 3.1–
^
3.3) [25]. Similarly, when
1anti-
^
CCP and RF were compared with respect to severity of structural
1damage in the Norfolk Arthritis Register, anti-
^
CCP+ at baseline was
1strongly associated with both prevalent erosions (OR 2.5) and
1developing erosions after 5 years (OR 10.2). Anti-
^
CCP exerted better
1performance than IgM RF (OR 1.6 and 3.4, respectively) [26]. In
1another comparative study, anti-
^
CCP had higher positive predictive
1value for erosive RA than RF, C-
^
reactive protein (CRP), ESR or matrix
1metalloproteinase-
^
3 (MMP-
^
3) [27].
13. Prognostic value of genetic factors
13.1. MHC genes as outcome measures
1Certain HLA-
^
DRB1⁎01 (HLA-
^
DR1) and HLA-
^
DRB1⁎04 (HLA-
^
DR4)
1alleles, also known as “shared epitopes” (SE), has been associated
1with susceptibility to and/or progression of RA [2,28–30]. SE is a risk
1factor for more severe, destructive RA, as well as for the develop-
1ment of extraarticular manifestations [2,28]. It is likely, that the SE
1itself may not be directly responsible for poorer prognosis, but it
1may rather inﬂuence outcome indirectly, via ACPA production
1[2,4,31]
^
. Indeed, SE is probably the primary risk factor for increased
1ACPA production in RA [4,28,29,31,32]. SE was not only associated
1with positive ACPA titers, but also with absolute serum ACPA
1levels [29]. Among HLA-
^
DRB1 alleles, ACPA production has been
1associated with HLA-
^
DRB1⁎04, rather than HLA-
^
DRB1⁎01 [2,11,29].
1Among
^
HLA-
^
DRB1⁎04 subtypes, DRB1⁎0401, ⁎0404, ⁎0405 and
1⁎0408 SE exerted the closest association with positive ACPA [2,33].
1In a recently published study, among 2221 single-
^
nucleotide poly-
1morphisms (SNPs) within the MHC region, 299 SNPs showed
1signiﬁcant associations with ACPA+ RA, while none of these SNPs
1could be associated with seronegative RA [34]. Among non-
^
SE HLA-
1
^
DRB1 alleles, HLA-
^
DRB1⁎13 and DRB1⁎15 have also been implicated
1in ACPA production [29]. Regarding various ACPAs, positive SE has
1been associated with anti-
^
CCP, anti-
^
CV and anti-
^
CF production
1[2,4,8,15,33,35]. In contrast, HLA-
^
DRB⁎03 (HLA-
^
DR3) may rather be
1associated with ACPA−
^
RA and milder disease course [2].ptide autoantibodies in association with genetic and environmental
mun Rev (2009), doi:10.1016/j.autrev.2009.04.006
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3.2. The prognostic value of non-
^
MHC genes
Regarding non-
^
HLA genes, the 1858C/T allele (rs2476601) poly-
morphism of PTPN22 has been associated with anti-
^
CCP+ and RF+ RA
[30,36,37]. This has also been conﬁrmed in UDP and early RA [37].
Fcγ receptors are key players in antigen presentation and inﬂam-
mation. In a cohort of 945 RA patients, Fcγ receptor IIIA (FcγRIIIA)
158V/F polymorphism was assessed and the VV genotype showed
clear association with ACPA+ RA [38].
In conclusion, SE, possibly otherMHC genes including HLA-
^
DRB1⁎13
and DRB1⁎15
^
and non-
^
MHC genes including PTPN22-
^
1858C/T
and FcγRIIIA-
^
158V/F alleles are associated with ACPA production and
thus, they may serve as indirect outcomemeasures. The use of multiple
indices, such as HLA-
^
DRB1+PTPN22+ACPA may exert even higher
prognostic value. In contrast, HLA-
^
DRB1⁎03 may confer ACPA serone-
gativity and better prognosis. However, there may be geographical
differences in the prognostic value of genetic factors described above
[2,11,29,30,32,33,35–38].
Regarding the comparison between genetic and immunological
markers as outcome measures, ACPA may have better predictive/
prognostic value than SE or PTPN22 polymorphism [30].
4. Environmental and lifestyle-
^
associated prognostic factors
Numerous studies have been performed with respect to the role
of environmental and lifestyle-
^
related factors, primarily smoking,
in susceptibility to the development and progress of RA. At least in
some geographical regions, smoking has been associated with the
development of extraarticular manifestations, including nodulosis
and cardiovascular complications, as well as with more progressive
disease course [33,39,40]. Yet, smoking may not be related to radio-
graphic progression [39]. It is likely, that smoking forms a “Bermuda
triangle” with SE and ACPA. Smoking promotes the citrullination of
synovial proteins and thus ACPA production [33,39]. In Scandinavian,
Dutch and French cohorts, a high risk for the development of ACPA+
RA was observed in patients carrying one or two SE alleles [33,39,40].
In SE+ patients, smoking is not only associated with positive ACPA, but
also with absolute serum anti-
^
CCP levels [33]. While, as described
above, primarily HLA-
^
DRB1⁎04 alleles have been associated with
ACPA production [2,11,29], in smokers, HLA-
^
DRB1⁎0101, ⁎0102 and
⁎1001 alleles showed the closest association with positive anti-
^
CCP
[33]. Smoking confers increased disease progression [39,40].
Regarding other environmental factors, based on studies, con-
ducted in Scandinavian cohorts, higher bodyweight at birth, the use of
oral contraceptives and excessive caffeine consumption
^
(N10/day)
conferred higher risk to develop ACPA+ RA. Interestingly, obesity was
associated with higher risk to seronegative RA. Red meat, vitamin D
and estrogen intake may be neutral in this respect, while moderate
wine consumption may decrease susceptibility [39,40]. In a Danish
cohort, SE+ heavy coffee drinkers had 53-
^
times, contraceptive users
had 45-
^
times higher risk to develop anti-
^
CCP+ RA [40].
5. Conclusion
In conclusion, RA patients may be classiﬁed into ACPA+ and ACPA−
^subpopulations that may have important prognostic signiﬁcance. The
terms “seropositive” and “seronegative”, originally based on the
evaluation of IgM RF, have undergone major transition. The develop-
ment of ACPA may precede the onset of clinical symptoms by years.
ACPA has predictive role in early, undifferentiated arthritis and ACPA+
individuals with UDP may have higher risk to develop RA. ACPA has
important prognostic role during the progression of RA and it is also
associated with more pronounced structural damage of the joints
indicated by radiographic progression. ACPA production has been
associated with certain genetic makeup, including the presence of SE,
or PTPN22 gene polymorphisms, as well as with environmental andPlease cite this article as: Szodoray P, et al, Anti-
^
citrullinated protein/pe
factors as indicators of disease outcome in rheumatoid arthritis, AutoimF
lifestyle-
^
related factors. Individuals carrying SE, or the PTPN22 1858T
allele, in addition to smoking exert increased radiographic progression
and unfavorable prognosis. Other factors, such as the use of oral
contraceptives, or excessive caffeine intake my also have relevance for
the development of ACPA+ RA. In clinical practice, a combination of
autoantibodies and genetic factors, in addition to clinical and radio-
graphic outcome measures should be determined in order to better
assess the outcome of RA and to enable optimal, early treatment.
^
Take-home messages
•
^
Synovial citrullination and the production of ACPA are crucial for the
pathogenesis and prognosis of rheumatoid arthritis.
•
^
ACPA production has been associated with genetic factors including
the shared epitope, PTPN22 polymorphism, as well as with lifestyle-
^
related factors, primarily, smoking.
•
^
The determination of ACPA in association with genetic and environ-
mental factors at the onset of the disease may serve as a complex
outcome measure in RA.TE
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